Biocon Biologics has one of the deepest portfolios of biosimilars in the industry, spanning insulins, monoclonal antibodies, and conjugated recombinant proteins, addressing diseases that impact billions globally — diabetes, cancer, autoimmune conditions, serious eye disorders, and bone health.
Our long-term investments in R&D have yielded a robust pipeline, with 10 biosimilars already commercialized across key markets and several others advancing through various stages of development. Our direct commercial presence in several advanced and emerging markets brings us closer to patients, payors, and healthcare systems, strengthening our position as a trusted global biosimilars leader.
